Early diagnosis of invasive fungal infections in hematooncological patients by serological methods

Czech version

Authors: Z. Ráčil ¹; I. Kocmanová ²; B. Wagnerová ¹; M. Lengerová ¹; J. Mayer ¹
Authors‘ workplace: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc. ¹; Oddělení klinické mikrobiologie FN Brno, pracoviště Bohunice, přednosta prim. MUDr. Alena Ševčíková ²
Published in: Vnitř Lék 2007; 53(9): 990-999
Category: Review

Overview

Invasive fungal infections have become one of the major causes of morbidity and mortality in hematooncological patients over the past 2 decades. Even there is an increasing incidence of invasive fungal infections caused by rare filamentous fungi, the majority of infections are caused by Candida sp. and especially Aspergillus sp. Early diagnosis and prompt initiation of antifungal treatment are leading factors influencing prognosis of patients with invasive fungal infection. Important advances in the field of early diagnosis of invasive fungal infections have been realized over the last years. Beside of new radiological methods the major progress has been done in serological methods. In this paper we review the most important of these serological methods and their position in routine clinical practice.

Key words:
hematological malignancies - invasive fungal infections - serological methods - galactomannan - mannan - antimannan - 1,3-β-D-glucan

Sources

1. Pfaller MA. Invasive Fungal Pathogens: Current Epidemiological Trends. Clin Infect Dis 2006; 43(Suppl 1): S3-S14.

2. Ruhnke M, Maschmeyer G. Management of mycoses in patients with hematologic disease and cancer - review of the literature. Eur J Med Res 2002; 7: 227-235.

3. O’Brien SN, Blijlevens NMA, Mahfouz TH et al. Infections in Patients with Hematological Cancer: Recent Developments. Hematology 2003; 2003: 438-472.

4. van Burik JH, Leisenring W, Myerson D et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246-254.

5. Groll AH, Shah PM, Mentzel C et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.

6. Yamazaki T, Kume H, Murase S et al. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732-1738.

7. Morgan J, Alexander B, Wannemuehler K. Quantification of Risk for Invasive Fungal Infection (IFI) among Transplant (TX) Recipients Reporting to TRANSNET. Program and abstracts of the 45th ICAAC Ocober 30-November 2, 2004; Washington, D.C., USA: Abstract M-1058.

8. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.

9. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.

10. Nolla-Salas J, Sitges-Serra A, Leon-Gil C et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23: 23-30.

11. von Eiff M, Roos N, Schulten R et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62: 341-347.

12. McLintock LA, Jones BL. Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients. Br J Haematol 2004; 126: 289-297.

13. Shao PL, Huang LM, Hsueh PR. Invasive fungal infection - laboratory diagnosis and antifungal treatment. J Microbiol Immunol Infect 2006; 39: 178-188.

14. Alexander BD, Pfaller MA. Contemporary Tools for Diagnosis and Management of Invasive Mycoses. Clin Infect Dis 2006; 43(Suppl 1): S15-S27.

15. Maertens J, Deeren D, Dierickx D et al. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis 2006; 19: 551-556.

16. Lehmann PF, Reiss E. Invasive aspergillosis: antiserum for circulating antigen produced after immunization with serum from infected rabbits. Infect Immun 1978; 20: 570-572.

17. Reiss E, Lehmann PF. Galactomannan antigenemia in invasive aspergillosis. Infect Immun 1979; 25: 357-365.

18. Wheat LJ. Galactomannan antigenemia detection for diagnosis of invasive aspergillosis, part I. Clin Microbiol Newsl 2005; 27: 51-57.

19. Quindos G New microbiological techniques for the diagnosis of invasive mycoses caused by filamentous fungi. Clin Microbiol Infect 2006; 12(Suppl 7): 40-52.

20. Maertens J, Verhaegen J, Demuynck H et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999; 37: 3223-3228.

21. Maertens J, Verhaegen J, Lagrou K et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-1610.

22. Maertens J, Van Eldere J, Verhaegen J et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186: 1297-1306.

23. Sulahian A, Boutboul F, Ribaud P et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001; 91: 311-318.

24. Herbrecht R, Letscher-Bru V, Oprea C et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898-1906.

25. Pinel C, Fricker-Hidalgo H, Lebeau B et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003; 41: 2184-2186.

26. Rovira M, Jimenez M, De La Bellacasa JP et al. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 2004; 77: 1260-1264.

27. Maertens J, Theunissen K, Verbeken E et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126: 852-860.

28. Marr KA, Balajee SA, McLaughlin L et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-649.

29. Marr KA, Laverdiere M, Gugel A et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-1769.

30. Wheat L. Galactomannan antigenemia detection for diagnosis of invasiveaspergillosis, Part II. Clin Microbiol Newsl 2005; 27: 59-63.

31. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-357.

32. Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 2003; 5: 158-166.

33. Lee YR, Choi YW, Lee KJ et al. CT halo sign: the spectrum of pulmonary diseases. Br J Radiol 2005; 78: 862-865.

34. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.

35. Boutboul F, Alberti C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34: 939-943.

36. Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004; 39: 1467-1474.

37. Musher B, Fredricks D, Leisenring W et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42: 5517-5522.

38. Viscoli C, Machetti M, Gazzola P et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40: 1496-1499.

39. Kami M, Ogawa S, Kanda Y et al. Early diagnosis of central nervous system aspergillosis using polymerase chain reaction, latex agglutination test, and enzyme-linked immunosorbent assay. Br J Haematol 1999; 106: 536-537.

40. Sendid B, Poirot JL, Tabouret M et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002; 51: 433-442.

41. Kappe R, Muller J. Rapid clearance of Candida albicans mannan antigens by liver and spleen in contrast to prolonged circulation of Cryptococcus neoformans antigens. J Clin Microbiol 1991; 29: 1665-1669.

42. Sendid B, Tabouret M, Poirot JL et al. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999; 37: 1510-1517.

43. Greenfield RA, Troutt DL, Rickard RC et al. Comparison of antibody, antigen, and metabolite assays in rat models of systemic and gastrointestinal candidiasis. J Clin Microbiol 1988; 26: 409-417.

44. Verduyn Lunel FM, Voss A, Kuijper EJ et al. Detection of the Candida antigen mannan in cerebrospinal fluid specimens from patients suspected of having Candida meningitis. J Clin Microbiol 2004; 42: 867-870.

45. Persat F, Topenot R, Piens MA et al. Evaluation of different commercial ELISA methods for the serodiagnosis of systemic candidosis. Mycoses 2002; 45: 455-460.

46. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12: 310-350.

47. Miyazaki T, Kohno S, Mitsutake K et al. (1-->3)-beta-D-glucan in culture fluid of fungi activates factor G, a limulus coagulation factor. J Clin Lab Anal 1995; 9: 334-339.

48. Miyazaki T, Kohno S, Mitsutake K et al. Plasma (1-->3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995; 33: 3115-3118.

49. Yoshida M, Obayashi T, Iwama A et al. Detection of plasma (1 --> 3)-beta-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997; 35: 371-374.

50. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.

51. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.

52. Pazos C, Ponton J, Del Palacio A Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.

53. Koo S, Bryar J, Page JH et al. Clinical utility of the (1-3)-ß-D-Glucan Assay. Program and abstracts of the 45th ICAAC Semptember 27-30, 2006; San Francisco, California, USA: Abstract M-1600.

54. Pickering JW, Sant HW, Bowles CA et al. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-5962.

55. Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354: 2834-2835.

56. Sims CR, Mohr J, Paetznick V. Correlation of Clinical Outcome with ß-glucan (BG) Levels in Pts With Invasive Candidiasis. Program and abstracts of the 45th ICAAC Semptember 27-30, 2006; San Francisco, California, USA: Abstract M-1599.

57. Kappe R, Schulze-Berge A. New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. J Clin Microbiol 1993; 31: 2489-2490.

58. Dalle F, Lopez J, Caillot D et al. False-positive results caused by cotton swabs in commercial Aspergillus antigen latex agglutination test. Eur J Clin Microbiol Infect Dis 2002; 21: 130-132.

59. Mennink-Kersten MA, Ruegebrink D, Klont RR et al. Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol 2005; 43: 3925-3931.

60. Ansorg R, van den Boom R, Rath PM. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 1997; 40: 353-357.

61. Blijlevens NM, Donnelly JP, Meis JF et al. Aspergillus galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. Transpl Infect Dis 2002; 4: 64-65.

62. Viscoli C, Machetti M, Cappellano P et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-916.

63. Adam O, Auperin A, Wilquin F et al. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917-920.

64. Knight F, Mackenzie DW. Aspergillus antigen latex test for diagnosis of invasive aspergillosis. Lancet 1992; 339: 188.

65. Swanink CM, Meis JF, Rijs AJ et al. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 1997; 35: 257-260.

66. Eloy O, Tabella C, Harzic M et al. Detection of circulating Candida albicans mannan and antimannan antibodies: useful for diagnosis of deep seated candidiasis. Ann Biol Clin (Paris) 2002; 60: 711-714.

67. Rimek D, Redetzke K, Steiner B et al. Experience with the Platelia Candida ELISA for the diagnostics of invasive candidosis in neutropenic patients. Mycoses 2004; 47: Suppl 1: 27-31.

68. Rimek D, Redetzke K, Singh J et al. Performance of the Candida mannan antigen detection in patients with fungemia. Mycoses 2004; 47(Suppl 1): 23-26.

69. Chen Y, Sun H, Wang J et al. Usefulness of Combined Detection of Mannanemia and Antimannan Antibodies for the Diagnosis of Invasive Candidiasis. Program and abstracts of the 44th ICAAC October 30-November 2, 2004; Washington, D.C., USA: Abstract M-264.

70. White PL, Archer AE, Barnes RA. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol 2005; 43: 2181-2187.

71. Prella M, Bille J, Pugnale M et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 2005; 51: 95-101.